Koyfin Home > Directory > Health Care > Intercept Pharmaceuticals > EBITDA / Interest Expenses

Intercept Pharmaceuticals EBITDA / Interest Expenses Chart (ICPT)

Intercept Pharmaceuticals annual/quarterly EBITDA / Interest Expenses from 2011 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Intercept Pharmaceuticals EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-4m a -54.54% increase of 2m year over year
  • Intercept Pharmaceuticals EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-6m a -28.87% increase of 2m year over year
  • Intercept Pharmaceuticals Annual EBITDA / Interest Expenses for 2019 was $-7m a -26.07% increase of 2m from 2018
  • Intercept Pharmaceuticals Annual EBITDA / Interest Expenses for 2018 was $-9m a -20.95% increase of 2m from 2017
  • Intercept Pharmaceuticals Annual EBITDA / Interest Expenses for 2017 was $-11m a -123.85% increase of 14m from 2016
Other Ratios Metrics:
  • Intercept Pharmaceuticals Total Debt / Capital for the quarter ending September 09, 2018 was $71m a -34.16% decrease of -24m year over year
  • Intercept Pharmaceuticals Other Liabilities for the quarter ending September 09, 2018 was $5m a -50.16% decrease of -3m year over year
  • Intercept Pharmaceuticals Total Debt / Equity for the quarter ending September 09, 2018 was $248m a -27.17% decrease of -67m year over year
View Chart On Koyfin

Quarterly ICPT EBITDA / Interest Expenses Data

06/2020$-4m
03/2020$-7m
12/2019$-7m
09/2019$-6m
06/2019$-6m
03/2019$-10m
12/2018$-10m
09/2018$-7m
06/2018$-9m
03/2018$-10m

Annual ICPT EBITDA / Interest Expenses Data

2019$-7m
2018$-9m
2017$-11m
2016$-25m